karyopharm therapeutics inc - KPTI
KPTI
Close Chg Chg %
7.31 0.05 0.68%
Closed Market
7.36
+0.05 (0.68%)
Volume: 141.56K
Last Updated:
Dec 31, 2025, 4:00 PM EDT
Company Overview: karyopharm therapeutics inc - KPTI
KPTI Key Data
| Open $7.31 | Day Range 7.30 - 7.43 |
| 52 Week Range 3.51 - 12.45 | Market Cap $125.49M |
| Shares Outstanding 17.05M | Public Float 15.85M |
| Beta 0.21 | Rev. Per Employee N/A |
| P/E Ratio N/A | EPS -$14.58 |
| Yield 0.00% | Dividend N/A |
| EX-DIVIDEND DATE | SHORT INTEREST N/A |
| AVERAGE VOLUME 253.81K |
KPTI Performance
| 1 Week | -1.08% | ||
| 1 Month | 28.00% | ||
| 3 Months | 15.36% | ||
| 1 Year | -27.45% | ||
| 5 Years | -96.83% |
KPTI Analyst Ratings
- Sell
- Under
- Hold
- Over
- Buy
Number of Ratings
6
Full Ratings ➔
About karyopharm therapeutics inc - KPTI
Karyopharm Therapeutics, Inc. is a commercial-stage pharmaceutical company, which engages in the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. The company was founded by Joseph Araujo, Ronald A. DePinho, Pamela A, Silver, Giulio Draetta, Michael G. Kauffman, and Sharon Shacham on December 22, 2008, and is headquartered in Newton, MA.
KPTI At a Glance
Karyopharm Therapeutics, Inc.
85 Wells Avenue
Newton, Massachusetts 02459-3298
| Phone | 1-617-658-0600 | Revenue | 145.24M | |
| Industry | Pharmaceuticals: Major | Net Income | -76,422,000.00 | |
| Sector | Health Technology | Employees | 279 | |
| Fiscal Year-end | 12 / 2025 | |||
| View SEC Filings |
KPTI Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 0.567 |
| Price to Book Ratio | N/A |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -1.412 |
| Enterprise Value to Sales | 1.158 |
| Total Debt to Enterprise Value | 1.157 |
KPTI Efficiency
| Revenue/Employee | 520,562.724 |
| Income Per Employee | -273,913.978 |
| Receivables Turnover | 4.721 |
| Total Asset Turnover | 0.717 |
KPTI Liquidity
| Current Ratio | 1.696 |
| Quick Ratio | 1.645 |
| Cash Ratio | 1.179 |
KPTI Profitability
| Gross Margin | 95.63 |
| Operating Margin | -82.24 |
| Pretax Margin | -52.58 |
| Net Margin | -52.619 |
| Return on Assets | -37.753 |
| Return on Equity | N/A |
| Return on Total Capital | -898.343 |
| Return on Invested Capital | -722.838 |
KPTI Capital Structure
| Total Debt to Total Equity | N/A |
| Total Debt to Total Capital | 2,286.635 |
| Total Debt to Total Assets | 118.311 |
| Long-Term Debt to Equity | N/A |
| Long-Term Debt to Total Capital | 1,994.358 |
- Income Statement
- Balance Sheet
- Cash Flow Statement
Annual Financials for Karyopharm Therapeutics Inc - KPTI
Collapse All in section
| All values USD millions. | 2021 | 2022 | 2023 | 2024 | 5-year trend |
|---|---|---|---|---|---|
Sales/Revenue
| 209.82M | 157.07M | 146.03M | 145.24M | |
Sales Growth
| +94.12% | -25.14% | -7.03% | -0.55% | |
Cost of Goods Sold (COGS) incl D&A
| 4.19M | 5.83M | 5.47M | 6.35M | |
COGS excluding D&A
| - | - | - | - | - |
Depreciation & Amortization Expense
| 789.00K | 621.00K | 530.00K | 340.00K | |
Depreciation
| 789.00K | 621.00K | 530.00K | 340.00K | |
Amortization of Intangibles
| - | - | - | - | - |
COGS Growth
| +13.98% | +39.20% | -6.21% | +15.99% | |
Gross Income
| 205.63M | 151.24M | 140.56M | 138.89M | |
Gross Income Growth
| +96.95% | -26.45% | -7.06% | -1.19% | |
Gross Profit Margin
| +98.00% | +96.29% | +96.25% | +95.63% |
| 2021 | 2022 | 2023 | 2024 | 5-year trend | |
|---|---|---|---|---|---|
SG&A Expense
| 296.54M | 293.44M | 270.10M | 258.33M | |
Research & Development
| 152.70M | 148.04M | 138.22M | 142.89M | |
Other SG&A
| 143.85M | 145.40M | 131.88M | 115.44M | |
SGA Growth
| +7.34% | -1.05% | -7.95% | -4.36% | |
Other Operating Expense
| - | - | - | - | - |
Unusual Expense
| - | 7.26M | (280.00K) | (44.70M) | |
EBIT after Unusual Expense
| (98.18M) | (141.92M) | (129.54M) | (74.74M) | |
Non Operating Income/Expense
| 407.00K | 2.00M | 10.59M | 35.80M | |
Non-Operating Interest Income
| 582.00K | 2.36M | 10.94M | 7.40M | |
Equity in Earnings of Affiliates
| - | - | - | - | - |
Interest Expense
| 26.05M | 25.00M | 23.82M | 37.42M | |
Interest Expense Growth
| -4.03% | -4.03% | -4.69% | +57.08% | |
Gross Interest Expense
| 26.05M | 25.00M | 23.82M | 37.42M | |
Interest Capitalized
| - | - | - | - | - |
Pretax Income
| (123.82M) | (164.92M) | (142.78M) | (76.36M) | |
Pretax Income Growth
| +36.81% | -33.19% | +13.43% | +46.51% | |
Pretax Margin
| -59.01% | -105.00% | -97.77% | -52.58% | |
Income Tax
| 268.00K | 369.00K | 323.00K | 57.00K | |
Income Tax - Current - Domestic
| - | - | - | - | - |
Income Tax - Current - Foreign
| - | - | - | - | - |
Income Tax - Deferred - Domestic
| - | - | - | - | - |
Income Tax - Deferred - Foreign
| - | - | - | - | - |
Income Tax Credits
| - | - | - | - | - |
Equity in Earnings of Affiliates
| - | - | - | - | - |
Other After Tax Income (Expense)
| - | - | - | - | - |
Consolidated Net Income
| (124.09M) | (165.29M) | (143.10M) | (76.42M) | |
Minority Interest Expense
| - | - | - | - | - |
Net Income
| (124.09M) | (165.29M) | (143.10M) | (76.42M) | |
Net Income Growth
| +36.78% | -33.20% | +13.43% | +46.60% | |
Net Margin Growth
| -59.14% | -105.23% | -97.99% | -52.62% | |
Extraordinaries & Discontinued Operations
| - | - | - | - | - |
Discontinued Operations
| - | - | - | - | - |
Net Income After Extraordinaries
| (124.09M) | (165.29M) | (143.10M) | (76.42M) | |
Preferred Dividends
| - | - | - | - | - |
Net Income Available to Common
| (124.09M) | (165.29M) | (143.10M) | (76.42M) | |
EPS (Basic)
| -24.7457 | -30.2838 | -18.7925 | -9.4067 | |
EPS (Basic) Growth
| +39.45% | -22.38% | +37.95% | +49.94% | |
Basic Shares Outstanding
| 5.01M | 5.46M | 7.61M | 8.12M | |
EPS (Diluted)
| -24.7457 | -30.2838 | -18.7925 | -9.4067 | |
EPS (Diluted) Growth
| +39.45% | -22.38% | +37.95% | +49.94% | |
Diluted Shares Outstanding
| 5.01M | 5.46M | 7.61M | 8.12M | |
EBITDA
| (90.13M) | (141.58M) | (129.01M) | (119.10M) | |
EBITDA Growth
| +47.26% | -57.09% | +8.88% | +7.68% | |
EBITDA Margin
| -42.95% | -90.14% | -88.34% | -82.01% |
Snapshot
| Average Recommendation | OVERWEIGHT | Average Target Price | 14.667 | |
| Number of Ratings | 6 | Current Quarters Estimate | -1.953 | |
| FY Report Date | 03 / 2026 | Current Year's Estimate | -5.898 | |
| Last Quarter’s Earnings | -1.955 | Median PE on CY Estimate | N/A | |
| Year Ago Earnings | -12.178 | Next Fiscal Year Estimate | -1.78 | |
| Median PE on Next FY Estimate | N/A |
Earnings Per Share
| This Quarter | Next Quarter | This Fiscal | Next Fiscal | |
|---|---|---|---|---|
| # of Estimates | 3 | 3 | 6 | 3 |
| Mean Estimate | -1.95 | -1.56 | -5.90 | -1.78 |
| High Estimates | -1.56 | -0.76 | -3.54 | 2.17 |
| Low Estimate | -2.55 | -2.55 | -10.25 | -4.92 |
| Coefficient of Variance | -26.90 | -58.33 | -41.80 | -203.02 |
Analysts Recommendations
| Current | 1 Month Ago | 3 Months Ago | |
|---|---|---|---|
| BUY | 4 | 4 | 3 |
| OVERWEIGHT | 1 | 1 | 2 |
| HOLD | 1 | 1 | 1 |
| UNDERWEIGHT | 0 | 0 | 0 |
| SELL | 0 | 0 | 0 |
| MEAN | Overweight | Overweight | Overweight |
SEC Filings for Karyopharm Therapeutics Inc - KPTI
| Filing Date | Type | Category | Amended |
|---|---|---|---|
| No results | |||
Insider Actions for Karyopharm Therapeutics Inc - KPTI
| Date | Name | Shares | Transaction | Value |
|---|---|---|---|---|
| Apr 8, 2025 | Richard A. Paulson President and CEO; Director | 82,739 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $3.74 per share | 309,443.86 |
| Mar 7, 2025 | Michael Mano SVP, General Counsel&Secretary | 21,047 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $6.29 per share | 132,385.63 |
| Mar 7, 2025 | Reshma Rangwala EVP & Chief Medical Officer | 29,272 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $6.29 per share | 184,120.88 |
| Mar 7, 2025 | Kristin Abate Chief Accounting Officer | 9,713 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $6.29 per share | 61,094.77 |
| Mar 7, 2025 | Sohanya Cheng EVP & Chief Commercial Officer | 34,314 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $6.29 per share | 215,835.06 |
| Mar 7, 2025 | Stuart Poulton EVP, Chief Development Officer | 27,414 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $6.29 per share | 172,434.06 |
| Mar 6, 2025 | Sohanya Cheng EVP & Chief Commercial Officer | 37,759 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Mar 6, 2025 | Kristin Abate Chief Accounting Officer | 1,866 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Mar 6, 2025 | Stuart Poulton EVP, Chief Development Officer | 9,166 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Mar 6, 2025 | Stuart Poulton EVP, Chief Development Officer | 10,000 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Mar 6, 2025 | Stuart Poulton EVP, Chief Development Officer | 30,962 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Mar 6, 2025 | Sohanya Cheng EVP & Chief Commercial Officer | 9,166 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Mar 6, 2025 | Sohanya Cheng EVP & Chief Commercial Officer | 10,833 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Mar 6, 2025 | Reshma Rangwala EVP & Chief Medical Officer | 9,166 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Mar 6, 2025 | Reshma Rangwala EVP & Chief Medical Officer | 10,833 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Mar 6, 2025 | Reshma Rangwala EVP & Chief Medical Officer | 32,859 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Mar 6, 2025 | Richard A. Paulson President and CEO; Director | 40,000 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |